As I recall, we held back on submitting the BTD fo
Post# of 157708
(Total Views: 522)
Posted On: 01/06/2022 6:13:29 PM
Re: generactor #114046
As I recall, we held back on submitting the BTD for mTNBC with brain metastasis because we wanted to see how the FDA responded to the first BTD submittal. This may be more of a question for Ohm, but I wonder if sacituzumab can penetrate the brain barrier.
Quote:
meaning leronlimab hasn't shown a substantial improvement over the approved SOC, sacituzumab
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.